Kymera Therapeutics
Clinical-stage biopharmaceutical company pioneering targeted protein degradation to address previously undruggable disease targets in oncology and immunology.
Notes
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD). The company leverages its proprietary Pegasus platform to develop small molecule protein degraders that harness the body's natural protein disposal system to selectively degrade disease-causing proteins that were previously considered undruggable.
The company went public in August 2020 on NASDAQ under the ticker KYMC. Kymera's approach enables it to target transcription factors, scaffolding proteins, and other protein classes that traditional drug modalities cannot address.
Team
- Nello Mainolfi, Ph.D. - Founder, President & Chief Executive Officer
- LinkedIn: linkedin.com/in/nello-mainolfi
- Jared Gollob, M.D. - Chief Medical Officer
- Bruce Jacobs, J.D. - Chief Financial Officer & Chief Business Officer
- Darrin Miles - Chief Operating Officer
Additional Research Findings
- Founded in 2016 by Nello Mainolfi, spun out of Nimbus Therapeutics
- Listed on NASDAQ (KYMC) since August 2020
- Headquarters in Watertown, Massachusetts
- Proprietary Pegasus platform for targeted protein degradation
- Lead programs include KT-474 (IRAK4 degrader) for autoimmune diseases
- Also developing programs in oncology and inflammation
- Backed by investors including Atlas Venture, Lilly Asia Ventures, and Fidelity Management